BR112013030986A2 - análogos de hiperforina, métodos de síntese e usos dos mesmos - Google Patents

análogos de hiperforina, métodos de síntese e usos dos mesmos

Info

Publication number
BR112013030986A2
BR112013030986A2 BR112013030986A BR112013030986A BR112013030986A2 BR 112013030986 A2 BR112013030986 A2 BR 112013030986A2 BR 112013030986 A BR112013030986 A BR 112013030986A BR 112013030986 A BR112013030986 A BR 112013030986A BR 112013030986 A2 BR112013030986 A2 BR 112013030986A2
Authority
BR
Brazil
Prior art keywords
hyperforin
analogs
present
synthesis methods
depression
Prior art date
Application number
BR112013030986A
Other languages
English (en)
Inventor
Brian A Sparling
David Moebius
Matthew D Shair
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of BR112013030986A2 publication Critical patent/BR112013030986A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/723—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic
    • C07C49/727—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
    • C07C49/733—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system having two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
    • C07C49/743—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups having unsaturation outside the rings, e.g. humulones, lupulones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/46—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing nine carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Epoxy Compounds (AREA)

Abstract

resumo patente de invenção: "análogos de hiperforina, métodos de síntese e usos dos mesmos". a presente invenção refere-se a um novo método enantiosseletivo de 11 etapas ao produto natural hiperforina, que permite acesso a uma ampla variedade de análogos de hiperforina. a presente invenção também fornece composições farmacêuticas compreendendo análogos de hiperforina inventivos. análogos de hiperforina sintetizados usando o método sintético presente são considerados úteis no tratamento de várias condições, incluindo, porém não limitadas a, depressão e condições caracterizadas por depressão, condições de pele inflamatórias, diabetes, asma, doença pulmonar obstrutiva crônica (copd), transtornos renais, e lesão cerebral isquêmica. hiperforina
BR112013030986A 2011-06-03 2012-06-01 análogos de hiperforina, métodos de síntese e usos dos mesmos BR112013030986A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161493250P 2011-06-03 2011-06-03
PCT/US2012/040379 WO2012167021A2 (en) 2011-06-03 2012-06-01 Hyperforin analogs, methods of synthesis, and uses thereof

Publications (1)

Publication Number Publication Date
BR112013030986A2 true BR112013030986A2 (pt) 2016-12-06

Family

ID=47260359

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013030986A BR112013030986A2 (pt) 2011-06-03 2012-06-01 análogos de hiperforina, métodos de síntese e usos dos mesmos

Country Status (13)

Country Link
US (1) US9321713B2 (pt)
EP (1) EP2714638A4 (pt)
JP (1) JP2014527508A (pt)
KR (1) KR20140041610A (pt)
CN (1) CN103732568A (pt)
AU (1) AU2012262084A1 (pt)
BR (1) BR112013030986A2 (pt)
CA (1) CA2837549A1 (pt)
IL (1) IL229742A0 (pt)
MX (1) MX2013014162A (pt)
RU (1) RU2013157954A (pt)
SG (1) SG195210A1 (pt)
WO (1) WO2012167021A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103980231B (zh) * 2014-06-04 2016-03-30 中国科学院上海有机化学研究所 一种五氟苯基环氧丙烷的合成方法
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
CN106496171B (zh) * 2016-10-20 2019-09-13 贵州省中国科学院天然产物化学重点实验室 具有抗肿瘤活性的多环多异戊烯基间苯三酚类化合物、其制备方法及应用
CN106967016B (zh) * 2017-04-25 2020-05-19 华中科技大学 贯叶连翘次生代谢产物中具有乙酰胆碱酯酶抑制作用化合物及分离制备和用途
CN109044999A (zh) * 2018-10-15 2018-12-21 上海市第六人民医院 贯叶金丝桃素在制备促进白色脂肪棕色化并且提高棕色脂肪活性的药物中的用途
DE102022129895A1 (de) 2022-11-11 2024-05-16 Technische Universität Dresden, Körperschaft des öffentlichen Rechts 4-Hydroxybicyclo[3.3.1]non-3-en-2,9-dion-Derivate und deren Verwendung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2320091A1 (en) 1998-02-13 1999-08-19 Dr. Willmar Schwabe Gmbh & Co. Stable hyperforin salts, methods of manufacturing them, and their use for the treatment of alzheimer's disease
IT1301679B1 (it) * 1998-06-10 2000-07-07 Indena Spa Derivati dell'iperforina, loro uso e formulazioni che licontengono.
WO2000054760A2 (en) * 1999-03-15 2000-09-21 Shaman Pharmaceuticals, Inc. Bicyclo (3.3.1) nonenes useful for the treatment of diabetes and hypertriglyceridemia
WO2000054785A2 (en) * 1999-03-15 2000-09-21 Shaman Pharmaceuticals, Inc. Stabilized bicyclo[3.3.1]nonenes and methods of use
DE10157033A1 (de) 2001-11-21 2003-05-28 Siegfried Seeber Substituierte Bicyclo[3.3.1]nonan-2,4,9-trione als pharmazeutische Wirkstoffe
ITMI20020871A1 (it) 2002-04-23 2003-10-23 Indena Spa Derivati alogenati dell'iperforina loro uso e formulazioni che li contengono
ITMI20020872A1 (it) * 2002-04-23 2003-10-23 Indena Spa Derivati dell'iperforina loro uso e formulazioni che li contengono

Also Published As

Publication number Publication date
EP2714638A2 (en) 2014-04-09
US9321713B2 (en) 2016-04-26
JP2014527508A (ja) 2014-10-16
MX2013014162A (es) 2014-09-08
WO2012167021A2 (en) 2012-12-06
US20140135287A1 (en) 2014-05-15
SG195210A1 (en) 2013-12-30
IL229742A0 (en) 2014-01-30
RU2013157954A (ru) 2015-07-20
EP2714638A4 (en) 2015-09-23
WO2012167021A3 (en) 2013-04-25
CN103732568A (zh) 2014-04-16
CA2837549A1 (en) 2012-12-06
AU2012262084A1 (en) 2014-01-09
KR20140041610A (ko) 2014-04-04

Similar Documents

Publication Publication Date Title
BR112013030986A2 (pt) análogos de hiperforina, métodos de síntese e usos dos mesmos
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
CL2013001340A1 (es) Compuestos derivados de isoindol-amida, pirrolo-piridin-amida y pirrolo-pirimimidin-amida, inhibidores de nampt y rock; composicion farmaceutica; y metodo para tratar hiperetension, insuficiencia cardiaca cronica, aterosclerosis, asma, enfermedad de alzheimer, enfermedad de parkinson y glaucoma, entre otras enfermedades.
MY178156A (en) Compounds and their use as bace inhibitors
ECSP088741A (es) Derivados de benzotriazol como agonistas del adrenoreceptor beta2
BR112014016165A2 (pt) compostos de benzaldeído substituído e métodos para seu uso no aumento da oxigenação do tecido
BR112014003382A2 (pt) análogos de (e)-n'-(1-feniletilideno)benzo-hidrazida substituída como inibidores de histona desmetilase
UY31208A1 (es) Acidos fenoxiacéticos y sales y solvatos de los mismos utiles como compuestos farmacéuticos para el tratamiento de trastornos respiratorios, composiciones farmacéuticas que los contienen y procedimientos para la preparacion de los mismos.
UY35963A (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
BR112012019032A2 (pt) "processo para purificação de etanol"
BR112013027340A2 (pt) processo para recuperar álcool com redução de água do topo de uma coluna de ácido
BR112014023898A2 (pt) moléculas de ácido nucleico artificiais compreendendo 5''utr top
TR201909777T4 (tr) Sübsti̇tüe ki̇nazoli̇nonlara yöneli̇k oral çabuk salimli formülasyonlar
BRPI0821039B8 (pt) formas sólidas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico, processo de preparação das mesmas, composições farmacêuticas compreendendo as mesmas e usos
BR112013023517A2 (pt) "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica"
CL2008000329A1 (es) Compuestos derivados de octahidro fenantreno sustituidos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar asma, dermatitis, enfermedad de alzheimer, depresion, enfermedad pulmonar, entre otras enfermedades.
CR20140554A (es) Compuestos de acido dimetil-benzoico
BR112014013483A2 (pt) análogo de insulina humana e derivado acilado do mesmo
NI201100099A (es) Nuevos compuestos 578.
ECSP066545A (es) Procedimiento para la preparación de sales de tiotropio, sales de tiotropio, así como formulaciones medicamentosas que las contienen
EA201691293A1 (ru) Гетероарильные производные бутановой кислоты в качестве ингибиторов lta4h
BR112013030264A2 (pt) ácidos acéticos de benzociclohepteno
CR20140571A (es) Sal de tipo camsilato
BR112013027033A2 (pt) separação da água a partir do etanol em bruto
MX2015003732A (es) Tratamiento de enfermedad de alzheimer leve y moderada.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2465 DE 03-04-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.